Angiogenesis

Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.

MK-0429 (L-000845704) (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.

Acriflavine is a fluorescent dye for labeling high molecular weight RNA.

An interferon-inducing antiviral agent

An inhibitor of HIF-PH

GSK 3008348 hydrochloride is a small molecule antagonist targeting integrin αvβ6 (IC 50 =1.50nM). GSK 3008348 hydrochloride also inhibits the activity of αvβ1 (IC 50 =2.83nM), αvβ3 (IC 50 =12.53nM), αvβ5 (IC 50 =4.00nM), and αvβ8 (IC 50 =2.26nM).

Fradafiban (BIBU-52) is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.

PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM.

LW6 is a hypoxia-inducing factor 1(HIF) inhibitor, which effectively inhibits HIF-1α accumulation by degrading HIF-1α, but does not affect HIF-1A mRNA level during hypoxia.

iRGD peptide (c(CRGDKGPDC)) is a cyclic peptide composed of 9 amino acids that can specifically bind to av integrin and then be enzymatically hydrolyzed to produce CRGDK/R, which interacts with neuropilin-1 (NRP-1), thereby triggering drug tissue penetration and having tumor targeting and tumor penetration properties.

BMS-986195 (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase (BTK), with an IC50 of 0.1 nM.

A HIF-1 inhibitor

THS-044 binding stabilizes the HIF2α PAS-B folded state, for regulating HIF2 activity in endogenous and clinical settings.

IDF-11774 is an orally administered HIF-1α inhibitor, with an IC 50 value of 3.65μM.

Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.

EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer.

CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.

ENMD-119 (ENMD 1198) (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-119 (ENMD 1198) is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization.

GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.

AFP464 (NSC710464 free base), is an active HIF-1α inhibitor with an IC50 of 0.25 μM, also is a potent aryl hydrocarbon receptor (AhR) activator.

Protease-Activated Receptor-4 is the agonist of proteinase-activated receptor-4 (PAR4).

PAR-4 agonist peptide, amide TFA (PAR-4-AP (TFA)) is a synthetic peptide primarily used to activate protease-activated receptor 4 (PAR-4) .

Enarodustat (JTZ-951) is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM.